Clinical Trial

A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety of HH-101 antibody, administered as monotherapy to participants with advanced solid tumors.
Trial Details
NCT Number NCT07554196
Lead Sponsor Huahui Health
Conditions Solid Tumor
Enrollment 12 participants
Start Date 2022-01-19
Primary Completion 2023-08-09 (estimated)
Study Completion 2024-03-21 (estimated)
Updated on ClinicalTrials.gov 2026-04-28